NASDAQ:ETNB

89bio Competitors

$26.28
-0.06 (-0.23 %)
(As of 04/9/2021 12:00 AM ET)
Add
Compare
Today's Range
$25.54
Now: $26.28
$26.43
50-Day Range
$21.79
MA: $24.20
$26.73
52-Week Range
$18.01
Now: $26.28
$42.36
Volume76,357 shs
Average Volume157,644 shs
Market Capitalization$524.18 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Competitors

89bio (NASDAQ:ETNB) Vs. RVNC, DRNA, AXSM, NGM, MORF, and KURA

Should you be buying ETNB stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to 89bio, including Revance Therapeutics (RVNC), Dicerna Pharmaceuticals (DRNA), Axsome Therapeutics (AXSM), NGM Biopharmaceuticals (NGM), Morphic (MORF), and Kura Oncology (KURA).

Revance Therapeutics (NASDAQ:RVNC) and 89bio (NASDAQ:ETNB) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, dividends, risk, analyst recommendations, institutional ownership, valuation and earnings.

Institutional & Insider Ownership

74.4% of Revance Therapeutics shares are held by institutional investors. Comparatively, 80.6% of 89bio shares are held by institutional investors. 4.8% of Revance Therapeutics shares are held by insiders. Comparatively, 18.1% of 89bio shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Profitability

This table compares Revance Therapeutics and 89bio's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Revance Therapeutics-5,818.87%-85.72%-44.85%
89bioN/A-49.56%-46.52%

Earnings and Valuation

This table compares Revance Therapeutics and 89bio's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Revance Therapeutics$410,000.004,897.57$-159,430,000.00($3.67)-7.66
89bioN/AN/A$-57,420,000.00($24.49)-1.07

89bio has lower revenue, but higher earnings than Revance Therapeutics. Revance Therapeutics is trading at a lower price-to-earnings ratio than 89bio, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of current recommendations and price targets for Revance Therapeutics and 89bio, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Revance Therapeutics00503.00
89bio00613.14

Revance Therapeutics currently has a consensus price target of $36.40, suggesting a potential upside of 29.40%. 89bio has a consensus price target of $62.4286, suggesting a potential upside of 137.55%. Given 89bio's stronger consensus rating and higher probable upside, analysts clearly believe 89bio is more favorable than Revance Therapeutics.

Summary

89bio beats Revance Therapeutics on 10 of the 13 factors compared between the two stocks.

Dicerna Pharmaceuticals (NASDAQ:DRNA) and 89bio (NASDAQ:ETNB) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, dividends, risk, analyst recommendations, institutional ownership, valuation and earnings.

Institutional & Insider Ownership

80.6% of Dicerna Pharmaceuticals shares are held by institutional investors. Comparatively, 80.6% of 89bio shares are held by institutional investors. 11.3% of Dicerna Pharmaceuticals shares are held by insiders. Comparatively, 18.1% of 89bio shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Profitability

This table compares Dicerna Pharmaceuticals and 89bio's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Dicerna Pharmaceuticals-88.81%-71.72%-16.60%
89bioN/A-49.56%-46.52%

Earnings and Valuation

This table compares Dicerna Pharmaceuticals and 89bio's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Dicerna Pharmaceuticals$23.90 million83.31$-120,460,000.00($1.76)-14.82
89bioN/AN/A$-57,420,000.00($24.49)-1.07

89bio has lower revenue, but higher earnings than Dicerna Pharmaceuticals. Dicerna Pharmaceuticals is trading at a lower price-to-earnings ratio than 89bio, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of current recommendations and price targets for Dicerna Pharmaceuticals and 89bio, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Dicerna Pharmaceuticals00603.00
89bio00613.14

Dicerna Pharmaceuticals currently has a consensus price target of $37.8333, suggesting a potential upside of 45.01%. 89bio has a consensus price target of $62.4286, suggesting a potential upside of 137.55%. Given 89bio's stronger consensus rating and higher probable upside, analysts clearly believe 89bio is more favorable than Dicerna Pharmaceuticals.

Summary

89bio beats Dicerna Pharmaceuticals on 8 of the 12 factors compared between the two stocks.

Axsome Therapeutics (NASDAQ:AXSM) and 89bio (NASDAQ:ETNB) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, dividends, risk, analyst recommendations, institutional ownership, valuation and earnings.

Profitability

This table compares Axsome Therapeutics and 89bio's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Axsome TherapeuticsN/A-62.33%-47.87%
89bioN/A-49.56%-46.52%

Institutional & Insider Ownership

63.6% of Axsome Therapeutics shares are held by institutional investors. Comparatively, 80.6% of 89bio shares are held by institutional investors. 26.0% of Axsome Therapeutics shares are held by insiders. Comparatively, 18.1% of 89bio shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Analyst Ratings

This is a breakdown of current recommendations and price targets for Axsome Therapeutics and 89bio, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Axsome Therapeutics101102.83
89bio00613.14

Axsome Therapeutics currently has a consensus price target of $146.90, suggesting a potential upside of 177.22%. 89bio has a consensus price target of $62.4286, suggesting a potential upside of 137.55%. Given Axsome Therapeutics' higher probable upside, analysts clearly believe Axsome Therapeutics is more favorable than 89bio.

Earnings and Valuation

This table compares Axsome Therapeutics and 89bio's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Axsome TherapeuticsN/AN/A$-68,350,000.00($2.01)-26.36
89bioN/AN/A$-57,420,000.00($24.49)-1.07

Axsome Therapeutics is trading at a lower price-to-earnings ratio than 89bio, indicating that it is currently the more affordable of the two stocks.

Summary

89bio beats Axsome Therapeutics on 7 of the 11 factors compared between the two stocks.

89bio (NASDAQ:ETNB) and NGM Biopharmaceuticals (NASDAQ:NGM) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, valuation, institutional ownership, risk, profitability, analyst recommendations and dividends.

Profitability

This table compares 89bio and NGM Biopharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
89bioN/A-49.56%-46.52%
NGM Biopharmaceuticals-91.64%-29.47%-25.58%

Insider and Institutional Ownership

80.6% of 89bio shares are held by institutional investors. Comparatively, 49.6% of NGM Biopharmaceuticals shares are held by institutional investors. 18.1% of 89bio shares are held by company insiders. Comparatively, 50.4% of NGM Biopharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a summary of current ratings and target prices for 89bio and NGM Biopharmaceuticals, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
89bio00613.14
NGM Biopharmaceuticals00523.29

89bio presently has a consensus target price of $62.4286, suggesting a potential upside of 137.55%. NGM Biopharmaceuticals has a consensus target price of $39.1111, suggesting a potential upside of 53.80%. Given 89bio's higher possible upside, equities research analysts clearly believe 89bio is more favorable than NGM Biopharmaceuticals.

Valuation & Earnings

This table compares 89bio and NGM Biopharmaceuticals' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
89bioN/AN/A$-57,420,000.00($24.49)-1.07
NGM Biopharmaceuticals$103.54 million18.84$-42,790,000.00($0.85)-29.92

NGM Biopharmaceuticals has higher revenue and earnings than 89bio. NGM Biopharmaceuticals is trading at a lower price-to-earnings ratio than 89bio, indicating that it is currently the more affordable of the two stocks.

Summary

NGM Biopharmaceuticals beats 89bio on 8 of the 13 factors compared between the two stocks.

89bio (NASDAQ:ETNB) and Morphic (NASDAQ:MORF) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, valuation, institutional ownership, risk, profitability, analyst recommendations and dividends.

Profitability

This table compares 89bio and Morphic's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
89bioN/A-49.56%-46.52%
MorphicN/A-36.62%-20.69%

Insider and Institutional Ownership

80.6% of 89bio shares are held by institutional investors. Comparatively, 61.5% of Morphic shares are held by institutional investors. 18.1% of 89bio shares are held by company insiders. Comparatively, 39.5% of Morphic shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a summary of current ratings and target prices for 89bio and Morphic, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
89bio00613.14
Morphic00203.00

89bio presently has a consensus target price of $62.4286, suggesting a potential upside of 137.55%. Morphic has a consensus target price of $63.3333, suggesting a potential upside of 6.71%. Given 89bio's stronger consensus rating and higher possible upside, equities research analysts clearly believe 89bio is more favorable than Morphic.

Valuation & Earnings

This table compares 89bio and Morphic's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
89bioN/AN/A$-57,420,000.00($24.49)-1.07
Morphic$16.98 million113.42$-43,330,000.00($2.69)-22.06

Morphic has higher revenue and earnings than 89bio. Morphic is trading at a lower price-to-earnings ratio than 89bio, indicating that it is currently the more affordable of the two stocks.

89bio (NASDAQ:ETNB) and Kura Oncology (NASDAQ:KURA) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, valuation, institutional ownership, risk, profitability, analyst recommendations and dividends.

Profitability

This table compares 89bio and Kura Oncology's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
89bioN/A-49.56%-46.52%
Kura OncologyN/A-30.96%-28.02%

Insider and Institutional Ownership

80.6% of 89bio shares are held by institutional investors. Comparatively, 94.7% of Kura Oncology shares are held by institutional investors. 18.1% of 89bio shares are held by company insiders. Comparatively, 11.0% of Kura Oncology shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a summary of current ratings and target prices for 89bio and Kura Oncology, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
89bio00613.14
Kura Oncology011002.91

89bio presently has a consensus target price of $62.4286, suggesting a potential upside of 137.55%. Kura Oncology has a consensus target price of $39.5455, suggesting a potential upside of 38.42%. Given 89bio's stronger consensus rating and higher possible upside, equities research analysts clearly believe 89bio is more favorable than Kura Oncology.

Valuation & Earnings

This table compares 89bio and Kura Oncology's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
89bioN/AN/A$-57,420,000.00($24.49)-1.07
Kura OncologyN/AN/A$-63,140,000.00($1.51)-18.92

Kura Oncology is trading at a lower price-to-earnings ratio than 89bio, indicating that it is currently the more affordable of the two stocks.

Summary

89bio beats Kura Oncology on 6 of the 11 factors compared between the two stocks.


89bio Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Revance Therapeutics logo
RVNC
Revance Therapeutics
1.7$28.13-1.4%$2.01 billion$410,000.00-6.12
Dicerna Pharmaceuticals logo
DRNA
Dicerna Pharmaceuticals
1.8$26.09-1.3%$1.99 billion$23.90 million-16.20Analyst Revision
News Coverage
Axsome Therapeutics logo
AXSM
Axsome Therapeutics
1.4$52.99-2.1%$1.98 billionN/A-19.70
NGM Biopharmaceuticals logo
NGM
NGM Biopharmaceuticals
1.8$25.43-3.8%$1.95 billion$103.54 million-19.12Gap Down
MORF
Morphic
1.1$59.35-3.0%$1.93 billion$16.98 million-38.04Insider Selling
Gap Down
Kura Oncology logo
KURA
Kura Oncology
1.6$28.57-0.8%$1.89 billionN/A-17.53
Seres Therapeutics logo
MCRB
Seres Therapeutics
1.7$20.58-0.1%$1.88 billion$34.51 million-17.59News Coverage
Madrigal Pharmaceuticals logo
MDGL
Madrigal Pharmaceuticals
1.7$117.02-0.4%$1.88 billionN/A-10.57
MacroGenics logo
MGNX
MacroGenics
1.2$31.16-1.3%$1.87 billion$64.19 million-9.96News Coverage
Amneal Pharmaceuticals logo
AMRX
Amneal Pharmaceuticals
1.6$5.96-2.7%$1.79 billion$1.63 billion14.54News Coverage
Pandion Therapeutics logo
PAND
Pandion Therapeutics
1.0$60.05-0.0%$1.77 billion$970,000.000.00
Five Prime Therapeutics logo
FPRX
Five Prime Therapeutics
1.4$37.94-0.1%$1.77 billion$14.87 million-14.16News Coverage
Applied Molecular Transport logo
AMTI
Applied Molecular Transport
2.0$48.93-21.0%$1.72 billionN/A0.00Insider Buying
Gap Down
Cytokinetics logo
CYTK
Cytokinetics
1.7$24.16-0.1%$1.72 billion$26.87 million-12.65
FibroGen logo
FGEN
FibroGen
1.8$18.57-1.3%$1.70 billion$256.58 million-7.11Analyst Downgrade
High Trading Volume
Unusual Options Activity
Analyst Revision
News Coverage
Cassava Sciences logo
SAVA
Cassava Sciences
0.9$41.57-1.3%$1.66 billionN/A-173.21
ADC Therapeutics logo
ADCT
ADC Therapeutics
1.7$23.99-7.6%$1.65 billion$2.34 million-10.17Gap Down
Myovant Sciences logo
MYOV
Myovant Sciences
1.3$18.15-1.2%$1.65 billionN/A-6.46Insider Selling
Prelude Therapeutics logo
PRLD
Prelude Therapeutics
1.4$35.26-6.0%$1.64 billionN/A0.00Insider Selling
News Coverage
Gap Down
Ironwood Pharmaceuticals logo
IRWD
Ironwood Pharmaceuticals
1.8$10.19-1.5%$1.64 billion$428.41 million14.77
Aurinia Pharmaceuticals logo
AUPH
Aurinia Pharmaceuticals
1.8$12.80-1.3%$1.63 billion$320,000.00-8.71Analyst Report
News Coverage
Harmony Biosciences logo
HRMY
Harmony Biosciences
1.4$28.32-0.2%$1.61 billionN/A0.00
Travere Therapeutics logo
TVTX
Travere Therapeutics
1.2$25.61-1.4%$1.55 billion$175.34 million-15.06
Zentalis Pharmaceuticals logo
ZNTL
Zentalis Pharmaceuticals
1.8$37.41-13.5%$1.54 billionN/A0.00Insider Selling
Gap Down
Generation Bio logo
GBIO
Generation Bio
1.8$27.20-5.3%$1.53 billionN/A0.00Insider Selling
News Coverage
Gap Down
Kronos Bio logo
KRON
Kronos Bio
1.7$27.28-0.3%$1.53 billionN/A0.00Lockup Expiration
News Coverage
uniQure logo
QURE
uniQure
1.7$33.74-5.2%$1.52 billion$7.28 million-8.95Gap Down
Heron Therapeutics logo
HRTX
Heron Therapeutics
1.7$16.60-4.0%$1.52 billion$145.97 million-6.72News Coverage
Gap Down
ImmunoGen logo
IMGN
ImmunoGen
1.5$7.56-3.8%$1.51 billion$82.27 million-18.44Unusual Options Activity
News Coverage
Gap Down
Aclaris Therapeutics logo
ACRS
Aclaris Therapeutics
0.8$28.96-0.4%$1.50 billion$4.23 million-21.45
ATBPD
Antibe Therapeutics
0.1$3.88-0.5%$1.50 billion$7.51 million-6.46Gap Down
Supernus Pharmaceuticals logo
SUPN
Supernus Pharmaceuticals
1.4$28.31-0.7%$1.50 billion$392.76 million11.75Analyst Revision
News Coverage
PMV Pharmaceuticals logo
PMVP
PMV Pharmaceuticals
1.4$33.30-2.3%$1.49 billionN/A0.00Insider Selling
News Coverage
Gap Down
Cara Therapeutics logo
CARA
Cara Therapeutics
1.6$29.19-5.9%$1.46 billion$19.89 million-13.77Unusual Options Activity
News Coverage
Gap Up
Zymeworks logo
ZYME
Zymeworks
1.8$31.00-1.5%$1.43 billion$29.54 million-8.22News Coverage
Endo International logo
ENDP
Endo International
1.3$6.20-1.0%$1.43 billion$2.91 billion-9.12Analyst Report
News Coverage
Zealand Pharma A/S logo
ZEAL
Zealand Pharma A/S
1.2$32.80-1.5%$1.42 billion$6.20 million-14.39News Coverage
Keros Therapeutics logo
KROS
Keros Therapeutics
1.6$60.16-4.3%$1.40 billionN/A0.00Gap Down
Theravance Biopharma logo
TBPH
Theravance Biopharma
1.6$20.95-3.9%$1.37 billion$73.41 million-4.43Gap Down
Arcutis Biotherapeutics logo
ARQT
Arcutis Biotherapeutics
1.6$26.62-3.5%$1.33 billionN/A-2.88Gap Down
OLMA
Olema Pharmaceuticals
1.6$32.84-0.4%$1.32 billionN/A0.00
COMPASS Pathways logo
CMPS
COMPASS Pathways
1.5$35.80-3.8%$1.31 billionN/A0.00Gap Down
Stoke Therapeutics logo
STOK
Stoke Therapeutics
1.4$34.35-2.6%$1.26 billionN/A-19.08News Coverage
Ocular Therapeutix logo
OCUL
Ocular Therapeutix
1.6$16.51-1.3%$1.26 billion$4.23 million-9.22Gap Down
Pliant Therapeutics logo
PLRX
Pliant Therapeutics
1.9$33.90-7.8%$1.21 billion$57.05 million0.00Gap Down
Kiniksa Pharmaceuticals logo
KNSA
Kiniksa Pharmaceuticals
1.7$17.69-2.5%$1.21 billionN/A-7.46
Phathom Pharmaceuticals logo
PHAT
Phathom Pharmaceuticals
1.8$38.49-0.2%$1.21 billionN/A-2.75Insider Selling
News Coverage
Innoviva logo
INVA
Innoviva
1.4$11.70-1.6%$1.19 billion$261.02 million5.97
Avid Bioservices logo
CDMO
Avid Bioservices
1.7$19.39-2.9%$1.18 billion$59.70 million-193.90Unusual Options Activity
Gap Down
Shattuck Labs logo
STTK
Shattuck Labs
1.4$28.23-3.0%$1.18 billionN/A0.00Lockup Expiration
Gap Up
This page was last updated on 4/11/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.